Artivion (AORT) announced data from the AMDS PERSEVERE clinical trial was presented in a Late-Breaking Science presentation at the 61st Annual ...

Oppenheimer reiterated its Outperform rating on Artivion Inc. (NYSE: AORT) shares, maintaining a $32.00 price target. The ...

Oppenheimer reiterated its positive stance on Artivion Inc. (NYSE:AORT), maintaining an Outperform rating and a $32.00 price target. The endorsement comes on the heels of Artivion's presentation of ...

Stent grafting of the true lumen led to improved aortic remodeling, expansion of the true lumen, and shrinkage of the false lumen. But the incidence of aortic-related complication, such as rupture ...

This abnormal backflow of blood leads to pathologic changes in the heart — remodeling — in order to maintain effective forward cardiac output. Aortic regurgitation (AR) may occur due to damage ...

However, the cumulative risk of graft migration appears to be higher in patients who required additional proximal aortic extenders at the time of the initial endovascular repair. Presented at the ...

Artivion, Inc. announced the presentation of clinical data from the PERSEVERE United States investigational device exemption (I ...